Resource impact statement
NICE has recommended ixazomib (with lenalidomide and dexamethasone) for use within the Cancer Drugs Fund (CDF) as an option for treating multiple myeloma in adults who have already had 2 or 3 lines of therapy.
Ixazomib (with lenalidomide and dexamethasone) will be available to the NHS in line with the managed access agreement (MAA) with NHS England. As part of this, NHS England and Takeda have a commercial access agreement that makes ixazomib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of ixazomib will be covered by the CDF budget. The guidance will be reviewed when the final analysis of the TOURMALINE-MM1 trial is available. The MAA will continue until this data is available. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.
It is estimated that between 400 and 800 people will be treated with ixazomib (with lenalidomide and dexamethasone) within the CDF during the course of the MAA period.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: 07 February 2018